UiPath (PATH) just checked several key boxes for investors at once, moving from GAAP losses to profit while accelerating revenue growth and doubling down on its agentic AI and automation platform ...

UiPath Inc. (PATH) is one of a bunch of software companies that went public in 2021, saw its shares subsequently collapse, and have seemingly never managed to make a recovery. And to be fair, many of ...

PATH is transitioning from an RPA provider to a leading agent AI platform, underpinned by strategic partnerships with Snowflake, Google, Microsoft, and Nvidia. PATH possesses every capability to take ...

The AI orchestration platform is seeing its revenue accelerate. However, the company is just starting to tap into its potential. Meanwhile, the stock is still cheap despite its recent surge. For those ...

A controversy is swirling at a Texas university. The trigger? A flowchart. On Dec. 1, the new chancellor of the Texas Tech University system sent professors a diagram laying out a chain of approval ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The FDA has approved its first at-home, nondrug therapy for depression, with a wearable brain stimulation headset developed by Flow Neuroscience. The agency issued a green light that covers the device ...

Dec 11 (Reuters) - The U.S. Food and Drug Administration has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to typical antidepressants that ...

Learn how the flow of costs impacts manufacturing firms, covering raw materials, work-in-process, finished goods, and cost of goods sold with practical examples and methods.

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...